Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in combination with chemotherapy hit the primary endpoint in the company’s Phase III KEYNOTE-522 in triple-negative breast cancer.
The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.
Amgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin.
Novartis released data showing sharply improved overall survival rates for the breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.
The FDA approved Novartis AG’s Piqray in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.
Merck & Co. Inc.’s blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.
Puma Biotechnology’s Nerlynx (neratinib), in combination with Roche’s chemotherapy drug Xeloda (capecitabine), showed a treatment advantage compared to Novartis’ Tykerb (lapatinib) and Xeloda in a Phase III breast cancer study.
An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan’s Daiichi Sankyo’s met the main goal in a mid-stage study, bolstering the companies’ position in a highly competitive oncology market.
Through consultation with physicians and patients, the Canadian Breast Cancer Network (CBCN) outlined five key recommendations for consideration when implementing biosimilars in oncology
The U.S. Food and Drug Administration approved Roche’s Kadcyla (trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.
